2017 IPO
Jounce Therapeutics Stock
Jounce Therapeutics is developing cancer immune-therapies to harness the immune system to attack cancerous cells and tumors.
Sign up today and learn more about Jounce Therapeutics Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Jounce Therapeutics Stock
Jounce Therapeutics is dedicated to transforming the treatment of cancer. The company is discovering and developing first-in-class cancer immunotherapies designed to harness the immune system to seek out and attack cancerous cells and tumors. Jounce’s proprietary product engine is driving this transformational approach, which has the potential to drive significantly more durable responses to treatment, extending and improving patients’ quality of life. Founded by world leaders in immunobiology, cancer biology and clinical and translational medicine, Jounce Therapeutics was launched in 2013 with funding from leading life sciences investor, Third Rock Ventures.
Funding History
| 2013-02-01 | $47.0M |
|---|---|
| 2015-04-01 | $56.0M |
Management
Director of Business Development and Operations
Jason Fuller
Founder
Padmanee Sharma
CBO
Jigar Raythatha
Interim CEO
Cary Pfeffer
Founder
Thomas F. Gajewski
Founder
Drew Pardoll
CTO
Robert I. Tepper
Interim Chief Technology Officer
Robert Kamen
CEO
Rich Murray
Vice President of Research
Michael Briskin
Press
EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
